SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Date of Report: June 15, 2000
BIORA AB
SE-205 12 Malmo, Sweden
Telephone: (011) 46-40-32-13-33
Indicate by a check mark whether the registrant files or
will file annual reports under cover of Form 20-F or Form 40-F.
|X| Form 20-F |_| Form 40-F
Indicate by check mark whether the registrant by furnishing
the information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
|_| Yes |X| No
If "Yes" is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b):
Not applicable.
This Form 6-K consists of two press releases issued by Biora
AB: one on June 8, 2000 regarding the hiring of a new executive at their
German division; and one on June 19, 2000 regarding the hiring of a new
Chief Executive Officer.
NO 8/00, JUNE 15, 2000
FOR IMMEDIATE RELEASE
Home page:www.biora.com
BIORA LAUNCHES EMDOGAIN(R)GEL AND "BIORA.COM" IN GENEVA
Biora (Nasdaq BIORY, SSE BIOR) launched their new formulation
Emdogain(R)Gel at "Europerio 3" June 8-11 in Geneva, Switzerland. Europerio
is Europe's largest convention for periodontists and is held every three
years.
Approximately 3,500 dental professionals attended this years meeting. The
participants were mainly European, however specialists from other parts of
the world were also represented.
The new formulation of Biora's principal product Emdogain attracted great
interest among the participants. Emdogain(R)Gel is delivered in a
pre-filled syringe, ready for immediate use. This improved delivery system
will assist Biora in its ambition to establish Emdogain as the standard
treatment for severe periodontitis.
"We are very pleased with the response to Emdogain(R)Gel and look forward
to the upcoming introduction in the North American market, where it will be
launched once regulatory approval has been received", says Tomas
Hammargren, President and CEO of Biora.
Several scientific reports regarding the efficacy of Emdogain were
presented during "Europerio 3". Among others, two of the world's leading
periodontists, Professor Lang of the University of Bern, Switzerland and
Professor Tonetti of Eastman Dental Center, London, UK presented a
multi-center clinical trial showing the positive results of Emdogain.
Biora's new website "biora.com" launched
Biora's new website "biora.com" was also launched during the
Europerio-meeting. The new site provides additional information regarding
Biora and its products for dental professionals, customers and investors.
Information for potential patients has also been improved to address many
of the questions that patients have about Emdogain treatment. This is the
first step in expanding Biora's Internet capabilities; future development
will include an e-commerce platform.
Biora develops manufactures and sells products for the treatment of
periodontal disease and for use in oral surgery. Using its proprietary
technology and expertise, Biora aims to become a world leader in
biology-based products for specialized dental therapy. Biora's American
Depository Shares are listed on the Nasdaq National Market in the US and
Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock
Exchange in Sweden.
This press release may contain certain forward- looking statements that
relate to future events or future business and financial performance. Such
statements can only be predictions and the actual events or results may
differ from those discussed. The Company cautions that these statements are
subject to important factors that could cause actual results to differ
materially from those expressed or implied in such forward looking
statements and are more fully discussed in periodic reports filed with
Securities and Exchange Commission.
NO 9/00, JUNE 19, 2000
FOR IMMEDIATE RELEASE
Home page: www.biora.com
RICKARD SODERBERG NEW CEO FOR BIORA AB
MALMO, SWEDEN, JUNE 19, 2000 - Biora AB (NASD: BIORY, SSE: BIOR) today
announces that Mr. Rickard Soderberg has been appointed President and CEO
of Biora AB. Mr. Soderberg will assume this position August 14, 2000.
Currently Mr. Soderberg, is Vice President of AstraZeneca with
responsibility for sales and marketing in Sweden. Mr. Tomas Hammargren, the
current President and CEO, will continue as a member of the Board and will
concentrate on strategic development issues.
- Tomas Hammargren has done an excellent job in building up the
organization during his six years as CEO for Biora, says Per Wahlstrom,
Chairman of the Board of Biora. At this time it is important to drive
Biora's expansion and increase the speed of our future development. Rickard
Soderberg has the background and possesses the qualities that are required
to do this in a successful way.
Rickard Soderberg is 42 years old and has extensive experience in the
pharmaceutical industry. He has previously held positions with Ferrosan AB,
Kabi Vitrum AB and Pharmacia Upjohn, where he was responsible for the
Austrian subsidiary.
Biora develops manufactures and sells products for the treatment of
periodontal disease and for use in oral surgery. Using its proprietary
technology and expertise, Biora aims to become a world leader in
biology-based products for specialized dental therapy. Biora's American
Depository Shares are listed on the Nasdaq National Market in the US and
Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock
Exchange in Sweden.
This press release may contain certain forward- looking statements that
relate to future events or future business and financial performance. Such
statements can only be predictions and the actual events or results may
differ from those discussed. The Company cautions that these statements are
subject to important factors that could cause actual results to differ
materially from those expressed or implied in such forward looking
statements and are more fully discussed in periodic reports filed with
Securities and Exchange Commission.
PRESIDENT AND CEO Investor Relations U.S Investor Relations
Tomas Hammargren Mikael Sjoblom Elisabeth Lavers
+46 40 32 13 36 + 46 40 32 13 65 +1 203 977 7797
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
BIORA AB
Dated: June 19, 2000 By: /s/ Anders Agering
--------------------------
Anders Agering
Chief Financial Officer
